Sofar, more than 100 different types of cannabinoids have been identified and thereis a growing body of evidence supporting the benefits of this class of compoundsin offering symptomatic relief for a wide variety of chronic health conditions
Overtime, extensive R&D on the potential health benefits of cannabis, haveenabled medical researchers to identify a number of pharmacologically activeingredients that offer clinical benefit, minus the addictive properties of thecrude substance. Currently, several stakeholders in the pharmaceutical industryare actively engaged in the efforts to develop leads based on natural andsynthetic derivatives of cannabinoids.
To order this 250+ pagereport, which features 140+ figures and 170+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/endocannabinoid-therapeutics/316.html
Over 175 drugstargeting the endocannabinoid system are currently under development
Most cannabinoid-baseddrug candidates are being developed to target the CB1 and CB2 receptors. Nearly45% of such drugs are presently being investigated in clinical trials, while 50%are in the preclinical / discovery phase. Majority of these therapies (60%) are designed for oraladministration.
More than60 companies claim to develop endocannabinoid system targeted therapeutics
Post2010, there has been a significant rise in the number of companies working inthis domain; such companies represent 63% of the total number of players. Majorityof the firms engaged in this domain (74%) are based in North America, followedby those headquartered in Asia-Pacific (16%), Europe (8%) and Latin America(2%).
Partnershipactivity has grown at an annualized rate of 35%, between 2017 and 2019
The maximumnumber of partnerships were observed in 2019 within this segment of thepharmaceutical industry. Majority of these agreements were reported to have beeninked for research purposes (20%). In addition, more than 35 merger /acquisition deal were signed between 2016 and 2020; service / facilityexpansion emerged as the most prominent key value drivers for such agreements.
Close to 600grants were awarded for supporting research on endocannabinoid system targetedtherapeutics, since 2016
Almost 45%of the total amount awarded in the form of grants, was under the R01 (insupport of health-related research and development based on the mission ofthe NIH) mechanism. Further, grants (394) worth USD 147 million wereawarded to research projects related to endocannabinoid system.
Atpresent, therapies intended for the treatment of neurological disorders representthe majority share of the overall endocannabinoid system targeted therapeuticsmarket
Most of the therapies targeting neurologicaldisorders are intended for the treatment of epilepsy. In addition to neurologicaldisorders, therapies intended for autoimmune disorders, cancer and geneticdisorders are likely to capture significant market opportunity in the foreseen future.
To request a sample copy /brochure of this report, please visit this - https://www.rootsanalysis.com/reports/316/request-sample.html
Key Questions Answered
§ Who are the leading industryplayers in this market?
§ What are the key clinicalconditions addressed by endocannabinoid system targeted therapeutics?
§ What are the biological receptorstargeted by cannabinoid-based therapies?
§ What are the factors that arelikely to influence the evolution of this market?
§ What are the initiatives undertakenby start-ups and big pharma players engaged in this domain?
§ What kind of partnership modelsare commonly adopted by stakeholders in this industry?
§ How is the current and futuremarket opportunity likely to be distributed across key market segments?
The over USD 5 billion (by 2030) financialopportunity within the endocannabinoid system targeted therapeutics market has been analyzed across thefollowing segments:
§ Target DiseaseIndication
- Genetic Disorders
- Neurological Indications
§ Route of Administration
§ Key Geographies
- North America
- Asia-Pacific and the Rest of the World
Thereport features inputs from eminent industry stakeholders, according to whom, endocannabinoidsystem targeted therapeutics are considered as a promising alternative for thetreatment of a diverse array of symptoms associated with a myriad of human diseases.The report includes detailed transcripts of the discussions held with industry experts.
§ OludareOdumosu (Chief Executive Officer, Zelira Therapeutics)
§ AndreaSmall-Howard (Chief Scientific Officer, GB Sciences)
§ SteeveNéron (Chief Operating Officer, Tetra Bio-Pharma)
§ StephenDahmer (Chief Medical Officer, Vireo Health)
§ AnthonyKievid (Director of Business Development, Echo Pharmaceuticals)
§ JANAKANKRISHNARAJAH (Chief Operating Officer and Chief Medical Officer, iX Biopharma)
Theresearch includes detailed profiles of key players (listed below); eachprofile features an overview of the company, its financial information (if available), drugportfolio, recent developments and an informed future outlook.
§ GW Pharmaceuticals
§ Corbus Pharmaceuticals
§ Tetra Bio-Pharma
§ Botanix Pharmaceuticals
§ Kalytera Therapeutics
§ Therapix Biosciences
§ Echo Pharmaceuticals
§ GB Sciences
For additional details, pleasevisit
https://www.rootsanalysis.com/reports/view_document/endocannabinoid-therapeutics/316.htmlor email email@example.com
You may also be interested in thefollowing titles:
1. Neoantigen TargetedTherapies Market,2019-2030
2. Blood-Brain Barrier(BBB) Market (2ndEdition), 2020-2030: Focus on Non-Invasive Drug Delivery Technology Platformsand Therapeutics
3. Bispecific AntibodyTherapeutics Market (4thEdition), 2019-2030
4. ContinuousManufacturing Market (SmallMolecules and Biologics), 2020 – 2030
+1 (415) 800 3415
+44(122) 391 1091